IL6 and cancer: Further, the enrichment of ‘INFLAMMATORY RESPONSE’ and inflammatory signaling (‘IL6 JAK STAT3 SIGNALING’ and ‘IL2 STAT5 SIGNALING’) pathways in the low-risk group might imply a higher degree of infiltration of anti-cancer immune cells (e.g., CD8+ T cells and dendritic cells) in this group of patients26.